Naxaprostene (CG 4305) is a prostacyclin analogue, which causes concentration dependent inhibition of thrombocyte function. Naxaprostene is more selective for IP receptors and tends towards partial agonism. Naxaprostene prevented thrombotic arterial occlusion in rabbits.

Deprostil is prostaglandin E analog. The drug exhibits a prolonged inhibition of basal gastric acid secretion. Deprostil is the orally active anti-ulcer agent. It is a racemate with four possible optical isomers. Like deprostil the (nat)- and (epi)-isomers appear to be potentially useful therapeutic agents for the treatment of hypergastrlc acid secretion and peptic ulcers.

Glunicate (LG 13979) is a long-acting nicotinic acid derivative that can lower plasma triglyceride levels, while leaving other lipoprotein parameters unaffected. It exerts a dose‐dependent reduction of plasma triglycerides and cholesterol. In rabbits, glunicate provided dose-dependent protection of the arterial wall from atheromatous lesions and from cholesterol and collagen accumulation. It has been shown that glunicate has prolonged activity on plasma free fatty acids and triglycerides, with long lasting and intense activity on plasma cholesterol.

Oglemilast (GRC-3886), is a potent and selective PDE4 inhibitor (IC50: 2.5 nM (PDE4B) and 1.7 nM (PDE4D)). Oglemilast is in phase II clinical trials for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Oglemilast was originally developed by Glenmark Pharmaceuticals, and licensed to Forest (acquired by Actavis in 2014) for the rights in North America in 2004. Teijin Pharma obtained the rights of the compound in Japan in 2005.

Dicloralurea is a herbicide and veterinary food additive that inhibits methane production in herbicide ruminants. It acts as a growth stimulant and now superseded.

Difenamizole is a non-steroidal anti-inflammatory drug and analgesic of the pyrazolone group related to metamizole. Mice given difenamizole per os showed maximal anti-nociceptive activity 30--60 min after administration. Difenamizole may depress the release of catecholamines from monoaminergic neurons. The analgesic action of difenamizole was antagonized by intracerebral injection of dopamine but not by norepinephrine. An analgesic action of difenamizole may be related to the dopaminergic system and difenamizole may depress the release of dopamine in the striatum, therefore, difenamizole may demonstrate an analgesic action following depression of dopaminergic neuronal activity in the striatum and preventing the binding of dopamine with the receptors.

Dichlormezanone is the skeletal muscle relaxant. This metathiazanone was found to have a mephenesin-like type of action characterized by paralyzing, anticonvulsant, and hypothermic activities. Dichlormezanone produced an ascending type of paralysis, associated with a marked ataxia. It has anti-electroshock and anti-chemoshock activities. It was found to be active after oral administration and to have a prolonged duration of action. The daily administration of sublethal doses of dichlormezanone to albino rats for 5 consecutive days produced only an initial loss of weight. No significant hematologic alteration or macroscopic lesion of any of the viscera, attributable to medication with either drug, was observed.

Dicirenone is an aldosterone antagonist. It is used as a hypotensive agent. Dicirenone inhibited the effects of aldosterone on urinary K(+):Na(+) ratios and the binding of [(3)H]aldosterone to renal cytoplasmic and nuclear receptors. Dicirenone blocked the action of aldosterone on Na-K ATPase. Cytoplasmic binding of [(3)H]aldosterone and dicirenone was similar in magnitude and involved the same set of sites. It had no effect on adrenal steroidogenesis.

Bemarinone (ORF 16600) is a positive inotropic and vasodilator agent with potential clinical utility in the management of congestive heart failure. The compound selectively and competitively inhibited cyclic AMP phosphodiesterase fraction III. However, further studies were discontinued

Ampyrimine is a diuretic agent.